Text this: Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

 __   __   _    _     ____      _____    __   __  
 \ \\/ // | || | ||  |  _ \\   |  ___||  \ \\/ // 
  \   //  | || | ||  | |_| ||  | ||__     \   //  
  / . \\  | \\_/ ||  | .  //   | ||__     / . \\  
 /_//\_\\  \____//   |_|\_\\   |_____||  /_//\_\\ 
 `-`  --`   `---`    `-` --`   `-----`   `-`  --`